Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study of SI-6603 in Patients with Lumbar Disc Herniation

Next Previous
Trial Profile

A Phase III Study of SI-6603 in Patients with Lumbar Disc Herniation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Condoliase (Primary)
  • Indications Intervertebral disc displacement
  • Focus Registrational; Therapeutic Use
  • Sponsors Seikagaku Corporation

Most Recent Events

  • 25 Sep 2024 Results published in a Ferring Pharmaceuticals Media Release
  • 25 Sep 2024 According to a Ferring Pharmaceuticals Media Release, data from two Phase 3 trials in the U.S. and one in Japan, evaluating efficacy and safety of SI-6603 being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH). The podium presentation at the North American Spine Society's (NASS) Annual Meeting
  • 09 Sep 2024 According to a Ferring Pharmaceuticals Media Release, an analysis of data from two Phase 3 trials for SI-6603, studied to treat radicular leg pain associated with lumbar disc herniation (LDH), will be presented at the North American Spine Societys (NASS) Annual Meeting to be held September 25-28, 2024, in Chicago, IL. The podium presentation includes evaluations of the efficacy and safety of SI-6603 from two Phase 3 clinical trials, one completed in the U.S., and one completed in Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top